









Markets
/
Stocks
/
nasdaq-cstl
/

Castle Biosciences Inc

CSTL

23.460USD

+1.640+7.52%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

679.90MMarket Cap

LossP/E TTM



Castle Biosciences Inc

23.460

+1.640+7.52%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

17 / 207

Overall Ranking

77 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

35.625

Target Price

+63.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 142.32% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 18.25M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -74.19, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.92M shares, decreasing 10.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.16M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.95.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.38, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 86.19M, representing a year-over-year decrease of 0.94%, while its net profit experienced a year-over-year decrease of 49.29%.

Score

Industry at a Glance

Previous score

8.38

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.91

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.83

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.18

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -69.01, which is -91.52% below the recent high of -5.85 and 72.73% above the recent low of -18.82.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 9.25, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Castle Biosciences Inc is 35.50, with a high of 41.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

9.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

35.625

Target Price

+63.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Castle Biosciences Inc

CSTL

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.04, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 24.63 and the support level at 19.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.04

Change

1.68

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.478

Neutral

RSI(14)

60.480

Neutral

STOCH(KDJ)(9,3,3)

38.889

Buy

ATR(14)

1.096

High Vlolatility

CCI(14)

-6.130

Neutral

Williams %R

36.994

Buy

TRIX(12,20)

0.613

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

22.014

Buy

MA10

22.803

Buy

MA20

22.551

Buy

MA50

19.895

Buy

MA100

18.984

Buy

MA200

21.921

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 96.24%, representing a quarter-over-quarter increase of 1.23%. The largest institutional shareholder is The Vanguard, holding a total of 2.16M shares, representing 7.43% of shares outstanding, with 13.87% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.31M

+2.35%

The Vanguard Group, Inc.

Star Investors

2.04M

+11.77%

Principal Global Investors (Equity)

1.47M

+2.24%

Portolan Capital Management, L.L.C.

1.61M

+27.34%

Dimensional Fund Advisors, L.P.

1.20M

+20.09%

Wasatch Global Investors Inc

Star Investors

998.46K

-44.41%

Braidwell LP

365.25K

Nuveen LLC

723.60K

+104.57%

State Street Global Advisors (US)

715.03K

+0.68%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.18, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.